Pharming Reports Positive Phase II Leniolisib Data in PIDs Beyond APDS
PHAR is trading near its 52-week low of $9.62 (15% above the low) on elevated volume (11× avg).
Summary
Pharming announced positive Phase II topline data for leniolisib in PIDs with immune dysregulation, showing a 26.4% mean spleen volume reduction and no new safety signals. The data supports expansion beyond APDS into a larger patient population, with a CVID readout expected in Q4 2026.
Key Events · Product Development and Regulatory · PHAR
-
Positive Phase II Leniolisib Data in PIDs
A single-arm, open-label, dose-escalation study in 13 subjects with genetically defined PIDs showed a mean 26.4% spleen volume reduction and reductions in index lesion size.
-
Favorable Safety Profile
No new safety signals were identified; infections were the most common adverse events, consistent with leniolisib's known safety profile.
-
Late-Breaking Abstract at ESID 2026
The data were accepted as a late-breaking abstract for the 22nd Biennial ESID Meeting, October 14-17, 2026, in the Netherlands.
-
CVID Phase II Readout Expected Q4 2026
Nine of 13 enrolled patients also had CVID; separate Phase II CVID topline results are expected in Q4 2026 to inform a potential registrational study.
Analysis · PHAR · Life Sciences
Positive topline Phase II data for leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling were disclosed today. The 13-patient study showed a mean 26.4% spleen volume reduction and reductions in index lesion size, with no new safety signals. This is the first clinical evidence supporting leniolisib's expansion beyond its approved APDS indication into a substantially larger patient population. The data will be presented as a late-breaking abstract at ESID 2026 in October, and a separate Phase II CVID readout is expected in Q4 2026. For a company whose Q2 2026 revenue declined 3% year-over-year and whose full-year guidance was cut by $30 million, a successful label-expansion pathway for its lead asset is a meaningful positive development.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $11.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $753.1M. The 52-week trading range was $9.62 to $21.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.